Foodborne Diseases Treatment Market, 2012-2023
Global Foodborne diseases cover a broad spectrum of illnesses that are affecting the people worldwide. These diseases are due to the intake of food contaminated with harmful microorganisms or chemicals. The contamination occurs from any way either soil, water or air. The most common foodborne infections are caused by three bacteria campylobacter, salmonella, and E.coli and by a group of viruses called calicivirus. Clinical symptoms of foodborne diseases seen in gastro intestinal tract. Symptoms include vomiting, diarrhea, and abdominal pain. In some cases, such diseases can also have neurological, gynecological, immunological and other symptoms. Common foodborne diseases include botulism, salmonellosis, traveler’s diarrhoea, gastroenteritis, tapeworm infection and hepatitis A, among others. Global foodborne diseases treatment market is driven by the increasing incidence of foodborne diseases worldwide.
Global Foodborne Diseases Treatment Market
Increase in R&D investment, growing awareness about foodborne disease symptoms due to initiatives of government and non-government organizations such as WHO, and lack of hygiene conditions are boosting the foodborne diseases treatment market worldwide. However, the high cost of R&D investment for development of anti microbial and stringent, time-consuming regulatory procedures are expected to hinder the foodborne diseases market.
Foodborne diseases treatment market has been segmented based on disease, drug class, and distribution channel
Based on drug class, foodborne diseases treatment market is segmented into
Geographically Foodborne Diseases Treatment Market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America foodborne diseases treatment market is expected to grow at notable rates due to increase in the prevalence of foodborne diseases such as botulism and toxoplasmosis, and increase in R&D investment by companies on antibiotics and vaccines. Asia Pacific and Africa regions are projecting lucrative opportunity for foodborne diseases treatment market owing to increase in the incidence of foodborne diseases in these regions. According to WHO estimates 2015, Africa and South East Asia regions have the highest incidence and death rates, including children under the age of 5 years. Europe is expected to show significant growth rate owing to increase in R&D investment and healthcare spending.
Some of the market players in foodborne diseases treatment market are Bayer AG (Germany), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), XOMA Corporation (U.S.), AlphaVax, Inc. (U.S.), Molecular Targeting Technologies, Inc. (U.S.), and Morphotek Inc. (U.S.) to name a few
In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler’s diarrhea
Global Foodborne Diseases Treatment Market
Increase in R&D investment, growing awareness about foodborne disease symptoms due to initiatives of government and non-government organizations such as WHO, and lack of hygiene conditions are boosting the foodborne diseases treatment market worldwide. However, the high cost of R&D investment for development of anti microbial and stringent, time-consuming regulatory procedures are expected to hinder the foodborne diseases market.
Foodborne diseases treatment market has been segmented based on disease, drug class, and distribution channel
Based on drug class, foodborne diseases treatment market is segmented into
- Antibiotics
- Anti Diarrhea
- Fluids and Electrolyte Replenishers
- Vaccines
- Others
- Botulism
- Traveler’s Diarrhea
- Gastroenteritis
- Toxoplasmosis
- Others
- Parenteral
- Oral
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Geographically Foodborne Diseases Treatment Market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America foodborne diseases treatment market is expected to grow at notable rates due to increase in the prevalence of foodborne diseases such as botulism and toxoplasmosis, and increase in R&D investment by companies on antibiotics and vaccines. Asia Pacific and Africa regions are projecting lucrative opportunity for foodborne diseases treatment market owing to increase in the incidence of foodborne diseases in these regions. According to WHO estimates 2015, Africa and South East Asia regions have the highest incidence and death rates, including children under the age of 5 years. Europe is expected to show significant growth rate owing to increase in R&D investment and healthcare spending.
Some of the market players in foodborne diseases treatment market are Bayer AG (Germany), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), XOMA Corporation (U.S.), AlphaVax, Inc. (U.S.), Molecular Targeting Technologies, Inc. (U.S.), and Morphotek Inc. (U.S.) to name a few
In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler’s diarrhea
1. EXECUTIVE SUMMARY
2. GLOBAL FOODBORNE DISEASE TREATMENT MARKET INTRODUCTION
2.1. Global Foodborne Disease Treatment Market – Taxonomy
2.2. Global Foodborne Disease Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Disease
2.2.3. Route of Administration
2.2.4. Distribution Channel
3. GLOBAL FOODBORNE DISEASE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Foodborne Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Foodborne Disease Treatment Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Foodborne Disease Treatment Market – Drug Class Pipeline Analysis
4. GLOBAL FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL FOODBORNE DISEASE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Antibiotics
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Anti Diarrhea
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Fluids and Electrolyte Replenishers
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Vaccines
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Botulism
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Traveler’s Diarrhea
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Toxoplasmosis
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Drug Stores
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antibiotics
10.1.2. Anti Diarrhea
10.1.3. Fluids and Electrolyte Replenishers
10.1.4. Vaccines
10.1.5. Others
10.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Botulism
10.2.2. Traveler’s Diarrhea
10.2.3. Gastroenteritis
10.2.4. Toxoplasmosis
10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Others
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. Drug Stores
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Foodborne Disease Treatment Market Dynamics – Trends
11. EUROPE FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antibiotics
11.1.2. Anti Diarrhea
11.1.3. Fluids and Electrolyte Replenishers
11.1.4. Vaccines
11.1.5. Others
11.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Botulism
11.2.2. Traveler’s Diarrhea
11.2.3. Gastroenteritis
11.2.4. Toxoplasmosis
11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Others
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.4.4. Drug Stores
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Foodborne Disease Treatment Market Dynamics – Trends
12. ASIA-PACIFIC FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antibiotics
12.1.2. Anti Diarrhea
12.1.3. Fluids and Electrolyte Replenishers
12.1.4. Vaccines
12.1.5. Others
12.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Botulism
12.2.2. Traveler’s Diarrhea
12.2.3. Gastroenteritis
12.2.4. Toxoplasmosis
12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Others
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.4.4. Drug Stores
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia-Pacific Foodborne Disease Treatment Market Dynamics – Trends
13. LATIN AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antibiotics
13.1.2. Anti Diarrhea
13.1.3. Fluids and Electrolyte Replenishers
13.1.4. Vaccines
13.1.5. Others
13.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Botulism
13.2.2. Traveler’s Diarrhea
13.2.3. Gastroenteritis
13.2.4. Toxoplasmosis
13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Others
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.4.4. Drug Stores
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Foodborne Disease Treatment Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Antibiotics
14.1.2. Anti Diarrhea
14.1.3. Fluids and Electrolyte Replenishers
14.1.4. Vaccines
14.1.5. Others
14.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Botulism
14.2.2. Traveler’s Diarrhea
14.2.3. Gastroenteritis
14.2.4. Toxoplasmosis
14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Others
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.4.4. Drug Stores
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Foodborne Disease Treatment Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. GE Healthcare (U.S.)
15.2.2. Hitachi, Ltd. (Hitachi Medical Corporation) (Japan)
15.2.3. Hologic, Inc. (U.S.)
15.2.4. Koninklijke Philips N.V. (Philips Healthcare) (Netherlands)
15.2.5. Siemens AG (Germany)
15.2.6. Carestream Health (U.S.)
15.2.7. Toshiba Corporation (Japan)
15.2.8. Shimadzu Corporation (Japan)
15.2.9. Fujifilm Holdings Corporation (Japan)
15.2.10. Esaote SpA (Italy)
16. RESEARCH METHODOLOGY
Key Assumptions and Acronyms
2. GLOBAL FOODBORNE DISEASE TREATMENT MARKET INTRODUCTION
2.1. Global Foodborne Disease Treatment Market – Taxonomy
2.2. Global Foodborne Disease Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Disease
2.2.3. Route of Administration
2.2.4. Distribution Channel
3. GLOBAL FOODBORNE DISEASE TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Foodborne Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Foodborne Disease Treatment Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Foodborne Disease Treatment Market – Drug Class Pipeline Analysis
4. GLOBAL FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL FOODBORNE DISEASE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Antibiotics
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Anti Diarrhea
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Fluids and Electrolyte Replenishers
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Vaccines
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Botulism
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Traveler’s Diarrhea
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Toxoplasmosis
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Drug Stores
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antibiotics
10.1.2. Anti Diarrhea
10.1.3. Fluids and Electrolyte Replenishers
10.1.4. Vaccines
10.1.5. Others
10.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Botulism
10.2.2. Traveler’s Diarrhea
10.2.3. Gastroenteritis
10.2.4. Toxoplasmosis
10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Others
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. Drug Stores
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Foodborne Disease Treatment Market Dynamics – Trends
11. EUROPE FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antibiotics
11.1.2. Anti Diarrhea
11.1.3. Fluids and Electrolyte Replenishers
11.1.4. Vaccines
11.1.5. Others
11.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Botulism
11.2.2. Traveler’s Diarrhea
11.2.3. Gastroenteritis
11.2.4. Toxoplasmosis
11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Others
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.4.4. Drug Stores
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Foodborne Disease Treatment Market Dynamics – Trends
12. ASIA-PACIFIC FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antibiotics
12.1.2. Anti Diarrhea
12.1.3. Fluids and Electrolyte Replenishers
12.1.4. Vaccines
12.1.5. Others
12.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Botulism
12.2.2. Traveler’s Diarrhea
12.2.3. Gastroenteritis
12.2.4. Toxoplasmosis
12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Others
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.4.4. Drug Stores
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia-Pacific Foodborne Disease Treatment Market Dynamics – Trends
13. LATIN AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antibiotics
13.1.2. Anti Diarrhea
13.1.3. Fluids and Electrolyte Replenishers
13.1.4. Vaccines
13.1.5. Others
13.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Botulism
13.2.2. Traveler’s Diarrhea
13.2.3. Gastroenteritis
13.2.4. Toxoplasmosis
13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Others
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.4.4. Drug Stores
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Foodborne Disease Treatment Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Antibiotics
14.1.2. Anti Diarrhea
14.1.3. Fluids and Electrolyte Replenishers
14.1.4. Vaccines
14.1.5. Others
14.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Botulism
14.2.2. Traveler’s Diarrhea
14.2.3. Gastroenteritis
14.2.4. Toxoplasmosis
14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Others
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.4.4. Drug Stores
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Foodborne Disease Treatment Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. GE Healthcare (U.S.)
15.2.2. Hitachi, Ltd. (Hitachi Medical Corporation) (Japan)
15.2.3. Hologic, Inc. (U.S.)
15.2.4. Koninklijke Philips N.V. (Philips Healthcare) (Netherlands)
15.2.5. Siemens AG (Germany)
15.2.6. Carestream Health (U.S.)
15.2.7. Toshiba Corporation (Japan)
15.2.8. Shimadzu Corporation (Japan)
15.2.9. Fujifilm Holdings Corporation (Japan)
15.2.10. Esaote SpA (Italy)
16. RESEARCH METHODOLOGY
Key Assumptions and Acronyms
